Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study on IgPro10 (Privigen) in Primary Immunodeficiency
2014-003772-23Phase 3
- Sponsor
- CSL Behring
- Start
- Apr 2015
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of polyvalent human immunoglobulin in Immunogenetic disorder, common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), sponsored by CSL Behring. Primary endpoint: Proportion of infusions with one or more temporally-associated adverse events.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
Immunogenetic disordercommon variable immunodeficiency (CVID)X-linked agammaglobulinemia (XLA)
Beyond the preview
Go deeper on 2014-003772-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003772-23.